PREMATURE OVARIAN FAILURE
Keywords:
Keywords: premature ovarian failure, ethiology,diagnose and treat.Abstract
POF is a fairly common problem. The age of cessation of ovarian function and the onset of menopause is influenced by a number of factors that can be divided into two groups: modifiable (medical, social, and environmental factors) and non-modifiable (genetic). Heredity is a powerful predictor of accelerated depletion of the follicular apparatus and the onset of early menopause.
References
1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027
2. Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547
3. Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1
4. van Kasteren Y.M., Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483
5. Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1
6. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046
7. Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110
8. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041
9. Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017
10. Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330
11. Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292
12. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415
13. Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374
14. Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261
15. Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for dia- betes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0
16. Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516
17. Ostberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypo- gonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.x
18. El Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003
19. Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512
20. Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82
21. Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358
22. Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010
